Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Angiotensin receptor blockers and myocardial infarction.

× No keyword cloud information.

12 in total

1. Blood-pressure reduction and cardiovascular risk in HOPE study.

Authors: P Sleight; S Yusuf; J Pogue; R Tsuyuki; R Diaz; J Probstfield
Journal: Lancet Date: 2001 Dec 22-29 Impact factor: 79.321

2. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.

Authors: E J Lewis; L G Hunsicker; W R Clarke; T Berl; M A Pohl; J B Lewis; E Ritz; R C Atkins; R Rohde; I Raz
Journal: N Engl J Med Date: 2001-09-20 Impact factor: 91.245

3. Is GSK guilty of fraud?

Authors:
Journal: Lancet Date: 2004-06-12 Impact factor: 79.321

4. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.

Authors: B M Brenner; M E Cooper; D de Zeeuw; W F Keane; W E Mitch; H H Parving; G Remuzzi; S M Snapinn; Z Zhang; S Shahinfar
Journal: N Engl J Med Date: 2001-09-20 Impact factor: 91.245

5. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors: Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristiansson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Journal: Lancet Date: 2002-03-23 Impact factor: 79.321

6. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial.

Authors: Hans Lithell; Lennart Hansson; Ingmar Skoog; Dag Elmfeldt; Albert Hofman; Bertil Olofsson; Peter Trenkwalder; Alberto Zanchetti
Journal: J Hypertens Date: 2003-05 Impact factor: 4.844

Review 7. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review.

Authors: Giovanni F M Strippoli; Maria Craig; Jonathan J Deeks; Francesco Paolo Schena; Jonathan C Craig
Journal: BMJ Date: 2004-09-30

8. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.

Authors: Stevo Julius; Sverre E Kjeldsen; Michael Weber; Hans R Brunner; Steffan Ekman; Lennart Hansson; Tsushung Hua; John Laragh; Gordon T McInnes; Lada Mitchell; Francis Plat; Anthony Schork; Beverly Smith; Alberto Zanchetti
Journal: Lancet Date: 2004-06-19 Impact factor: 79.321

9. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.

Authors: Christopher B Granger; John J V McMurray; Salim Yusuf; Peter Held; Eric L Michelson; Bertil Olofsson; Jan Ostergren; Marc A Pfeffer; Karl Swedberg
Journal: Lancet Date: 2003-09-06 Impact factor: 79.321

10. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials.

Authors: Koon Teo; Salim Yusuf; Peter Sleight; Craig Anderson; Farouk Mookadam; Barbara Ramos; Lutz Hilbrich; Janice Pogue; Helmut Schumacher
Journal: Am Heart J Date: 2004-07 Impact factor: 4.749

42 in total

1. Angiotensin receptor blockers and myocardial infarction: cautions voiced are biologically credible.

Authors: Zaheer R Yousef; Francisco Leyva; Christopher Gibbs
Journal: BMJ Date: 2005-05-28

2. Angiotensin receptor blockers and myocardial infarction: direct comparative studies are needed.

Authors: Lionel H Opie
Journal: BMJ Date: 2005-05-28

3. Angiotensin receptor blockers and myocardial infarction: analysis of evidence is incomplete and inaccurate.

Authors: John McMurray
Journal: BMJ Date: 2005-05-28

4. Angiotensin receptor blockers and myocardial infarction: results reflect different cardiovascular states in patients with types 1 and 2 diabetes.

Authors: Edmund J Lewis
Journal: BMJ Date: 2005-05-28

5. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice.

Authors:
Journal: Heart Date: 2005-12 Impact factor: 5.994

6. [Cardioprotection by means of Candesartan in cardiac insufficiency. CHARM overall partial evaluation (Candesartan in heart failure assessment of reduction in mortality and morbidity)].

Authors: C Tschöpe; H P Schultheiss
Journal: Internist (Berl) Date: 2006-10 Impact factor: 0.743

7. Role of RAAS Inhibition in the Prevention of Cardiovascular Disease.

Authors: Henry A Tran; Arthur Schwartzbard; Howard S Weintraub
Journal: Curr Treat Options Cardiovasc Med Date: 2011-08

8. Imidapril: will fewer adverse events translate into better long-term outcomes?

Authors: Tom Richart; Jan A Staessen; Willem H Birkenhäger
Journal: Drugs Date: 2007 Impact factor: 9.546

Review 9. 2010 position paper of the Italian Society of Hypertension (SIIA): angiotensin receptor blockers and risk of cancer.

Authors: Massimo Volpe; Alberto Morganti
Journal: High Blood Press Cardiovasc Prev Date: 2011-03-01

Review 10. The role of angiotensin II type 1 receptor antagonists in elderly patients with hypertension.

Authors: G Neil Thomas; Paul Chan; Brian Tomlinson
Journal: Drugs Aging Date: 2006 Impact factor: 3.923